… lives through transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today … addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the offering … cash and cash equivalents, to primarily fund research and development and clinical development to support the …
… retinal disease, into the clinic and continuing the development of our portfolio of transformative RNA medicines … ProQR. “QR-421a has shown promising activity in both the optic cup and zebra fish models and we are excited about the … gene and will be conducted at expert sites in the US and Europe. It will be a double-masked, randomized study …
… pigmentosa (adRP) due to the P23H mutation in the rhodopsin ( RHO ) gene. Fast Track designation is granted … ) gene. The trial will include a single-dose escalation (open label) arm and a multiple-dose (double-masked) arm in … of visual function and retinal structure through ophthalmic endpoints such as visual acuity (BCVA), visual …
… are no therapies commercially available or in clinical development for the vision loss associated with this disease. … preclinical data in both patient fibroblasts and the optic cup model for mRNA restoration, which was presented at … of the Association for Research in Vision and Ophthalmology (ARVO) in May 2017. A lead candidate has been …
… lives through transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today … addition, ProQR has granted the underwriters a 30-day option to purchase up to 2,700,000 additional ordinary shares … prevalent diseases with unmet need. Based on its unique proprietary RNA repair platform technologies ProQR is growing …
Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s commitment to advance the development of therapies for central nervous system diseases
… L’Agence européenne des médicaments accorde l’accès PRIME au … et seulement 20 % (une sur cinq) des demandes en ophtalmologie l'avaient été. « La décision de l’EMA … prometteuses de son programme principal en ACL10. À propos du Sepofarsen Le Sepofarsen est le premier …
… ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa The trial, called WINGS, … with recessive dystrophic epidermolysis bullosa (RDEB) is open for enrollment. “The initiation of our first human … clinical trial for QR-313 is an exciting next step in the development of this novel investigational therapy for DEB. …